A Randomized, Open-label, Single-dose, Four-way Crossover Pilot Study in Healthy Subjects to Assess the Pharmacokinetic Characteristics and Relative Bioavailability of Hydromorphone Following Administration of 3 Different Hydromorphone Tamper Resistant Formulations (12 mg) in the Fed and Fasted State, Compared to Palladone® (12 mg) in the Fed and Fasted State (HMP1017)

Authors

Jeffrey L. Huston, Cedarville UniversityFollow

Role

Lead Pharmacist

Sponsor

Purdue Pharma, L.P

Location

Stamford, CT

Recommended Citation

Huston, Jeffrey L., "A Randomized, Open-label, Single-dose, Four-way Crossover Pilot Study in Healthy Subjects to Assess the Pharmacokinetic Characteristics and Relative Bioavailability of Hydromorphone Following Administration of 3 Different Hydromorphone Tamper Resistant Formulations (12 mg) in the Fed and Fasted State, Compared to Palladone® (12 mg) in the Fed and Fasted State (HMP1017)" (2006). Pharmacy Faculty Research. 14.
https://digitalcommons.cedarville.edu/pharmacy_research/14